doi: 10.1161/hc4601.099489
(Circulation. 2001;104:2525.)
© 2001 American Heart Association, Inc.
Clinical Investigation and Reports |
Activated Interstitial Myofibroblasts Express Catabolic Enzymes and Mediate Matrix Remodeling in Myxomatous Heart Valves
From the Department of Pathology (E.R., J.R.S., F.J.S.) and the Leducq Center for Cardiovascular Research, Cardiovascular Division, Department of Medicine (M.A., Y.F., P.L.), Brigham and Women’s Hospital, Harvard Medical School, Boston, Mass.
Correspondence to Frederick J. Schoen, MD, PhD, Department of Pathology, Brigham and Women’s Hospital, 75 Francis Street, Boston, MA 02115. E-mail fjschoen{at}partners.org
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionConclusionsReferences |
|---|
Background The mechanisms of extracellular matrix changes accompanying myxomatous valvular degeneration are uncertain.
Methods and Results To test the hypothesis that valvular interstitial cells mediate extracellular matrix degradation in myxomatous degeneration by excessive secretion of catabolic enzymes, we examined the functional characteristics of valvular interstitial cells in 14 mitral valves removed for myxomatous degeneration from patients with mitral regurgitation and in 11 normal mitral valves obtained at autopsy. Immunohistochemical staining assessed (1) cell phenotype using antibodies to 
-actin (microfilaments), vimentin and desmin (intermediate filaments), smooth muscle myosin (SM1), and SMemb (a nonmuscle myosin produced by activated mesenchymal cells) and (2) the expression of proteolytic activity using antibodies to collagenases (matrix metalloproteinase [MMP]-1, MMP-13), gelatinases (MMP-2, MMP-9), cysteine endoproteases (cathepsin S and K), and interleukin-1ß, a cytokine that can induce secretion of proteolytic enzymes. Although interstitial cells in normal valves stained positively for vimentin, but not -actin or desmin, cells in myxomatous valves contained both vimentin and -actin or desmin (characteristics of myofibroblasts). Moreover, cells in myxomatous valves strongly expressed SMemb, MMPs, cathepsins, and interleukin-1ß, which were weakly stained in controls. Nevertheless, interstitial cells in both groups strongly expressed procollagen-I mRNA (in situ hybridization), suggesting preserved ability to synthesize collagen in myxomatous valves.
Conclusions Interstitial cells in myxomatous valves have features of activated myofibroblasts and express excessive levels of catabolic enzymes, without altered levels of interstitial collagen mRNA. We conclude that valvular interstitial cells regulate matrix degradation and remodeling in myxomatous mitral valve degeneration.
Key Words: mitral valve • remodeling • metalloproteinases • collagen
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionConclusionsReferences |
|---|
Myxomatous degeneration is the pathological substrate of mitral valve prolapse, a common cardiac valvular disorder characterized by redundant, floppy leaflets and associated with progressive mitral regurgitation, thromboembolism, infective endocarditis, and sudden death.1,2 Floppy valves likely result from mechanically inadequate extracellular matrix (ECM), particularly collagen, thereby allowing stretching of the leaflets.2,3 Nevertheless, the mechanisms responsible for the ECM defect and/or reparative processes that bolster the defective ECM are uncertain.
As in other tissues, turnover of the valvular ECM depends on a dynamic balance between synthesis and degradation. In most tissues, degradation of the ECM occurs through the action of matrix metalloproteinases (MMPs) and cysteine endoproteases (cathepsins). In cardiac valves, tight regulation of matrix homeostasis stringently maintains the functional architecture of the normal valve.4 Therefore, we propose that dysregulation of matrix metabolism modulates major features of the abnormalities of collagen and other ECM in heart valves with myxomatous degeneration.
The present study evaluated the role of valvular interstitial cells and catabolic enzymes such as MMPs and cathepsins in the pathogenesis of myxomatous degeneration using valves from patients who required surgery for severe mitral regurgitation, had myxomatous degeneration on pathological examination, and had no other documented condition known to predispose to mitral regurgitation.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionConclusionsReferences |
|---|
Mitral valves with myxomatous degeneration derived from valve repair (n=13) or replacement surgery (n=1) and normal mitral valves from autopsy (n=11) were obtained according to a protocol approved by the Human Research Committee at the Brigham and Women’s Hospital. Detailed review of clinical charts revealed that none of the patients with myxomatous valve degeneration had documented coronary artery disease or other conditions known to predispose to mitral regurgitation (Tables 1 and 2).
|
|
Morphological Characterization
Specimens were fixed in 10% buffered formalin and embedded in paraffin. Serial sections (6 µm) were stained with hematoxylin and eosin for general morphology, Movat pentachrome stain for connective tissue elements (differentially stains collagen, elastin, and proteoglycans),5 and picrosirius red for collagen architecture and evaluation of collagen types I and III.6,7
Characterization of Myofibroblasts and Detection of Catabolic Enzymes
Myofibroblasts were distinguished by antibody reaction to cytoskeletal filaments (smooth muscle -actin [microfilaments] and vimentin and desmin [intermediate filaments; DAKO])8; and by negative staining to the myosin antibodies SM1 (differentiated smooth muscle cells) and SM2 (mature smooth muscle cells)9,10 (Table 3). Combined use of these antibodies serves as useful markers to distinguish smooth muscle cells from myofibroblast-like cells. A classification system of myofibroblasts is based on immunohistochemical staining of cytoskeletal filaments.11 Myofibroblasts that express vimentin and -actin are called VA type, those that express vimentin and desmin are called VD type, and those that express vimentin, -actin, and desmin are called VAD type. Differentiated smooth muscle cells were determined by immunoreaction to SM1 and SM2 antibodies. Inflammatory cells were identified with antibodies to CD68 (macrophages) and CD45 (T cell; DAKO). Mouse monoclonal antibodies against human MMP-1, MMP-2, MMP-9, and MMP-13 (Oncogene Research Products), and rabbit anti-human cathepsin S and cathepsin K were used to determine the expression of collagenolytic and elastolytic enzymes. Expression of interleukin (IL)-1ß (a pro-inflammatory cytokine that induces the expression of MMPs) was examined with goat polyclonal anti-human IL-1ß (Santa Cruz Biotechnology), and cell activation was demonstrated by a monoclonal antibody to SMemb9,10 (a nonmuscle myosin also known as MHC-B). Immunohistochemistry was done using the avidin-biotin-peroxidase method after antigen retrieval. Double immunofluorescent staining7 was done to confirm coexpression of Il-1ß and MMP-13 or cathepsin S. Adjacent sections treated with nonimmune IgG served as controls for antibody specificity.
|
In Situ Hybridization
Nonisotopic in situ hybridization for human procollagen-I mRNA was done according to the manufacturer’s instructions (InnoGenex). Sections were incubated with oligomers as follows: anti-sense: 5'-GCT GTC CCT TCA ATC CAT CCA GAC CA-3', 5'-TAA CCA AAG TCA TAA CCA CCA CCG C-3', 5'-CAT AGT CCT TGG GTC TGA G-3'; sense: 5'-TGG TCT GGA TGG ATT GAA GGG ACA GC3', 5'-GCG GTG GTG GTT ATG ACT TTG CTT A-3', 5'-CTC AGA CCC AAG GAC TAT G-3'.
Quantification and Statistical Analysis
Immunohistochemical staining of MMPs and in situ hybridization for procollagen-I mRNA expression were graded as follows: 0, no appreciable staining; 1, weak in <50% of cells; 2, weak in 
50% of cells or strong in >10% of cells; 3, strong in 10% to 50% of cells; and 4, strong in 50% of cells. Semiquantitative analysis was done by E.R. and an observer without the knowledge of the origin of tissue or antibodies. Valve thickness was measured using a linear eyepiece reticle (10 mm, 0.1 mm division) (Fisher Scientific) for each section in the middle portion of each leaflet and was expressed as a mean of 3 measurements. Cell density was expressed as mean number of cells per 10 high power fields. Quantitative data were compared in both groups by Mann-Whitney’s U test. Data are presented as mean±SEM. P<0.05 was considered significant.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionConclusionsReferences |
|---|
Myxomatous Valves Show Altered Morphology
Figure 1 compares the histological features of normal and myxomatous valves. Analogous to aortic valves,4 normal mitral valves had 3 well-defined tissue layers (Figure 1A), each containing cells and characteristic ECM composition and configuration: (1) the fibrosa, which is composed predominantly of collagen fibers arranged parallel to the free edge of the leaflet, densely packed and microscopically crimped; (2) the centrally located spongiosa, which is composed of loosely arranged collagen and proteoglycans; and (3) the atrialis, which is composed of elastic fibers. In contrast, myxomatous valves showed: (1) expansion of the spongiosa by loose, amorphous ECM staining strongly positive for proteoglycans (blue/green on Movat staining); (2) diminished staining for collagen fibers (yellow); and (3) fragmentation of elastin (black). Picrosirius red staining under polarized light further demonstrated that individual collagen bundles were fragmented, coiled, disrupted, and disoriented in myxomatous leaflets; collagen fibers were almost undetectable in the spongiosa and had lower birefringence than those in normal valves. Myxomatous valves often had a layer of superficial plaque characterized by the accumulation of stellate and spindle-shaped cells, particularly on the ventricular aspect of the leaflet. Owing to both expansion of the spongiosa and plaque formation, myxomatous leaflets were significantly thicker than normal (2.27±0.1 mm versus 0.92±0.08 mm, respectively; P<0.0001; Figure 1B).
|
Inflammatory cells, including macrophages and T-cells, were negligible in myxomatous valves. The cell density in the spongiosa of myxomatous valves was significantly increased (approximately tripled) compared with normal (62.9±5.5 and 21.2±1.3 cells per high power field, respectively; P<0.0001; Figure 1C).
Myxomatous Valves Contain Activated Myofibroblasts
Myofibroblast-like cells accumulated in myxomatous leaflets (Figure 2). In normal valves, interstitial cells expressed vimentin (V phenotype), but not -actin or SM1. Cells stained with -actin and antibodies to SM1 and SM2 localized in the proximal (near annulus) and middle portions and distributed predominantly in regions adjacent to the atrial aspect of the leaflet. In myxomatous valves, in contrast, many cells in the deeper portion of the atrialis and in the spongiosa expressed vimentin and -actin or desmin, but not SM1 or SM2, suggesting modulation of a quiescent form of interstitial cells with V phenotype in normal valves to myofibroblasts with VA or VD phenotypes11 in myxomatous valves.
|
Activated interstitial cells accumulated in myxomatous but not in normal valves (Figure 3). Almost all interstitial cells in myxomatous leaflets stained for SMemb, which is known to be expressed by activated mesenchymal cells9,10 whereas cells in normal leaflets were not immunoreactive to SMemb (Figure 3A). Activated (both spindle-shaped and stellate) myofibroblasts were dispersed in a random fashion in the "myxoid" stroma, which was composed mainly of proteoglycans and sparse, loosely arranged collagen fibrils (Figure 3A). In the superficial plaque, myofibroblasts strongly expressed SMemb and MMPs and had the VA phenotype (Figure 3B).
|
Myxomatous Valves Overexpress Proteolytic Enzymes
Interstitial cells in myxomatous valves expressed higher levels of catabolic enzymes than in normal valves, especially collagenases (MMP-1, MMP-13; Figure 4A). Semiquantitative analysis showed that levels of MMP-1, MMP-13, MMP-2, and MMP-9 in myxomatous valves (grades 3.1±0.2, 3.3±0.13, 2.07±0.2, and 2.08±0.2, respectively) were significantly higher than those in normal (grades 1.27±0.2, 0.91±0.3, 1.18±0.2, and 1.27±0.1; P=0.0002, P=0.0001, P=0.02, and P=0.03, respectively; Figure 4B). In normal valves, sparse macrophages could be responsible for low levels of proteolytic enzymes.
|
Normal valves contained no cathepsin S or K or IL-1ß (data not shown). In myxomatous, interstitial cells immunoreactive to IL-1ß, MMP-13 and cathepsin K colocalized with loose collagen and fragmented elastin in areas of myxomatous degeneration (Figure 4C). Immunofluorescent double-labeling for catabolic enzymes and IL-1ß also showed coexpression of MMP-13/IL-1ß and cathepsin S/IL-1ß by interstitial cells in the spongiosa of myxomatous valves (Figure 4D).
Collagen-I mRNA Expression Is Similar in Myxomatous and Normal Valves
In situ hybridization using oligomers specific for human procollagen-I detected mRNA expression by interstitial cells in both normal and myxomatous valves (Figure 5A). Semiquantitative grading of procollagen-I mRNA expression showed no significant difference between normal (3.1±0.3) and myxomatous valves (3.4±0.25; P=NS; Figure 5B).
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionConclusionsReferences |
|---|
This study showed that myxomatous valves have significant thickening and highly abnormal layered architecture and ECM components and that interstitial cells in myxomatous leaflets (1) exhibited features of activated myofibroblasts, (2) expressed elevated levels of proteolytic enzymes, (3) retained the ability to express interstitial collagen, and (4) significantly increased in number in the spongiosa. These results suggest that dysregulation of matrix metabolism modulates the abnormalities in collagen and other ECM components in this pathological condition.
Valvular Functional Architecture
Heart valves have a complex, layered architecture and highly specialized, functionally adapted cells and ECM.4,12 The ECM elements accommodate repetitive changes in shape and dimension throughout the cardiac cycle; interstitial cells synthesize the ECM and mediate its ongoing repair and remodeling, thereby providing durability. Each of the valvular layers is enriched in a specific ECM component and has a distinct function. These features have been demonstrated predominantly in the aortic valves. Although less work has been done to understand structure-function correlations in the normal mitral valve, the general architecture and roles of the layers are likely analogous to those of the aortic valve. In the normal aortic valve, the collagen of the fibrosa permits maximum leaflet coaptation during closure (ie, prevent cuspal prolapse) and is essential for the maintenance of valve durability. The elastin of the ventricularis expands during diastole and recoils in systole. The hydrophilic proteoglycans in the normal valvular spongiosa have a cushioning and shear absorbing function.4 For the mitral valve, leaflet coaptation in the closed phase requires coordinated movements of the mitral apparatus.
Myxomatous Valve Degeneration
The pathogenesis of the connective-tissue abnormalities causing floppy mitral valve remains uncertain. In some cases, there is an identified genetic/congenital defect in connective tissue (ie, Marfan syndrome).13 Moreover, a genetic defect has been postulated for idiopathic/isolated mitral valve prolapse.14 Other cases likely result from either acquired abnormalities of valvular connective tissue geometry, composition, or context (ie, ischemic papillary muscle dysfunction and functional mitral regurgitation in heart failure).
In the present study of myxomatous valves from patients without known contributory systemic illness or cardiac disorder, interstitial cells expressed considerable collagenolytic enzymes but maintained collagen synthesis. These observations suggest that the abnormalities of collagen result primarily from excessive collagenolytic activity rather than decreased collagen synthesis. The deranged mechanical properties of myxomatous valves result from defective ECM and altered layered architecture. Indeed, a recent study demonstrated dramatic defects in the mechanical properties of myxomatous leaflets and chordae; myxomatous leaflets were more extensible and half as strong as normal valve tissue, which suggested that the abnormal stresses engendered by progressive stretching of enlarged leaflets and inherent weakness are synergistic in valve degeneration, possibly following as well as preceding valve repair.15
Interstitial Valvular Cells
The physiological role of valvular cells in the maintenance and remodeling of ECM in normal valves and their dysregulation in disease are poorly understood. The resting interstitial cell population of normal cardiac valves is predominantly fibroblast-like. These cells synthesize collagen, elastin, and proteoglycans. However, smooth muscle cells and myofibroblasts have also been cultured from heart valves.16–18 Myofibroblasts may well represent an intermediate state between fibroblasts and smooth muscle cells. Detection of myofibroblasts is difficult because of their heterogeneity and absence of particular immunohistochemical markers. Characterization of myofibroblasts is based on antibody reaction to 2 filament systems of cells composed of (1) actin (a component of the microfilaments) and (2) vimentin, desmin, and laminin (members of the intermediate filament system).8 In the present study, interstitial cells in normal valves expressed vimentin, but not -actin or desmin, although other investigators have often observed -actin–positive cells cultured from cardiac valves and characterized them as myofibroblasts.16–18 In control valve specimens, only smooth muscle cells displayed -actin and SM1. Interestingly, in myxomatous leaflets, many cells in deep atrialis and spongiosa expressed vimentin, as well as -actin or desmin but not SM1, suggesting that under pathological conditions interstitial cells may express features of VA or VD phenotypes of myofibroblasts.
The expression of MMPs, cathepsins, and IL-1ß in myxomatous lesions and associated superficial plaques suggest activation of valvular cells. Activation of myofibroblasts was confirmed by SMemb, which is predominantly expressed by activated mesenchymal cells.9,10 Stellate myofibroblasts (large cells with long cytoplasmic extensions) were found in loose myxomatous stroma. These cells can be a local source of multiple cytokines and catabolic enzymes that affect cell proliferation, activation, and ECM accumulation. They can be found in restenotic lesions after angioplasty or stenting,19 suggesting similar mechanisms of myofibroblast activation, differentiation, proliferation, and ECM degradation.
Role and Mechanisms of Matrix Remodelling in Myxomatous Mitral Valve Degeneration
Members of a family of enzymes that includes interstitial collagenases and gelatinases, MMPs are involved in the matrix breakdown in normal and pathological conditions such as atherosclerosis6,7 and aortic aneurysms.13 Interstitial collagenases mediate the initial step of collagen degradation by breakdown of the native helix of the fibrillar collagen network (type I is most abundant, comprising 
70% of the total collagen in valves).20 These fragments then become accessible to the other proteases, such as gelatinases, which further catabolize collagen.21 Cathepsins S and K are also involved in ECM remodeling, particularly elastin.22 Cathepsin K, the most potent elastase yet described, also has collagenolytic activity.
Several lines of evidence suggest that resident cells mediate ECM degradation in many degenerative diseases. Stimulation of these cells in some way elicits soluble extracellular messengers that, in turn, induce resident cells to initiate matrix degradation.23 For example, cardiac catabolic factor, which is derived from porcine heart valves, stimulates collagen and proteoglycan degradation in vitro. It has properties similar to those of catabolin, a cytokine first detected in porcine synovium and considered a form of porcine IL-1.24 Previous studies have shown that cultured smooth muscle cells exposed to IL-1ß release MMP-2, MMP-9, and cathepsins S and K.22,25
The present study indicates that resident valvular cells contribute to matrix destruction and remodeling in myxomatous valves. Interstitial valvular cells were the major source of the significantly increased expression of proteolytic enzymes, such as MMPs, that mediate ECM degradation and were significantly increased in number compared with normal valves, suggesting cell proliferation. Our study also demonstrated the presence of interstitial cells immunoreactive for cathepsins S and K and strongly expressing IL-1ß in the myxomatous valves. Moreover, IL-1ß co-localized with MMP-13 and cathepsin S. These observations suggest that interstitial cells induced by IL-1ß could mediate the expression of catabolic enzymes and modulate the development of the defective ECM by enzymatic breakdown of the connective tissue first described by Caulfield et al26 in myxomatous valves.
The present study provides new insight into mechanisms by which ongoing and progressive matrix degeneration may contribute to a common clinical pathway. These data clearly establish that interstitial cells express excessive catabolic enzymes in valves with myxomatous degeneration. However, it remains to be determined whether high proteolytic activity and cell activation in the mitral leaflets are causal or whether regurgitation and abnormal mechanical stress induce matrix remodeling as a reactive mechanism. Nevertheless, these observations on diseased human tissues cannot definitely resolve the nature of the primary stimulus to myxomatous degeneration. Our data implicate a progression of cell/tissue level to clinical events, which is summarized schematically in Figure 6. They also suggest a mechanism by which progressive deterioration of myxomatous tissue could occur after otherwise successful valve repair surgery.
|
|
Conclusions |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionConclusionsReferences |
|---|
Taken together, these results suggest that the altered layered architecture of the leaflet and structural abnormalities of connective tissue components, as well as excessive levels of collagenolytic and elastolytic enzymes expressed by activated interstitial cells, could cause the leaflet functional abnormalities of myxomatous valves in patients with mitral regurgitation.
|
Acknowledgments |
|---|
This project was supported in part by National Heart, Lung, and Blood Institute grant PO1 HL-48743 (to P.L.). The authors thank Dr Richard N. Mitchell for critical review of this work, Dr Guo-Ping Shi (University of California, San Francisco) for the anti-cathepsin antibodies, Eugenia Shvartz and Dmitriy Zvagelsky for technical assistance, Karen Williams for editorial expertise, and Claudia Davis for preparing the manuscript.
Received July 5, 2001; revision received September 5, 2001; accepted September 12, 2001.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionConclusionsReferences |
|---|
1. Guthrie RB, Edwards JE. Pathology of the myxomatous mitral valve. Nature, secondary changes and complications. Minn Med. 1976; 59: 637–647.[Medline] [Order article via Infotrieve]
2.
Davies MJ, Moore BP, Braimbridge MV. The floppy mitral valve: study of incidence, pathology, and complications in surgical, necropsy, and forensic material. Br Heart J. 1978; 40: 468–481.
3. Tamura K, Fukuda Y, Ishizaki M, et al. Abnormalities in elastic fibers and other connective-tissue components of floppy mitral valve. Am Heart J. 1995; 129: 1149–1158.[Medline] [Order article via Infotrieve]
4. Schoen FJ. Aortic valve structure-function correlations: Role of elastic fibers no longer a stretch of the imagination. J Heart Valve Dis. 1997; 6: 1–6.[Medline] [Order article via Infotrieve]
5. Russell HK. A modification of the Movat pentachrome stain. Arch Pathol. 1972; 94: 187–191.[Medline] [Order article via Infotrieve]
6.
Aikawa M, Rabkin E, Okada Y, et al. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma. Circulation. 1998; 97: 2433–2444.
7.
Sukhova GK, Schonbeck U, Rabkin E, et al. Evidence for increased collagenolysis by interstitial collagenases-1 and –3 in vulnerable human atheromatous plaques. Circulation. 1999; 99: 2503–2509.
8. Powell DW, Mifflin RC, Valentich JD, et al. Myofibroblasts, I: paracrine cells important in health and disease. Am J Physiol. 1999; 277: C1–C19.
9.
Aikawa M, Rabkin E, Voglic SJ, et al. Lipid lowering promotes accumulation of mature smooth muscle cells expressing smooth muscle myosin heavy chain isoforms in atheroma of hypercholesterolemic rabbits. Circ Res. 1998; 83: 1015–1026.
10.
Aikawa M, Sivam PN, Kuro-o M, et al. Human smooth muscle myosin heavy chain isoforms as molecular markers for vascular development and atherosclerosis. Circ Res. 1993; 73: 1000–1012.
11. Schurch W, Seemayer TA, Gabbiani G. The myofibroblast: a quarter century after its discovery. Am J Surg Path. 1998; 22: 141–147.[Medline] [Order article via Infotrieve]
12. Schoen FJ, Levy RJ. Tissue heart valves: current challenges and future research perspectives. J Biomed Mater Res. 1999; 47: 439–465.[Medline] [Order article via Infotrieve]
13. Segura AM, Luna RE, Horiba K, et al. Immunohistochemistry of matrix metalloproteinases and their inhibitors in thoracic aortic aneurysms and aortic valves of patients with Marfan’s syndrome. Circulation. 1998; 98: II-331–II-338.
14.
Glesby MJ, Pyeritz RE. Association of mitral valve prolapse and systemic abnormalities of connective tissue: a phenotypic continuum. J Am Med Assoc. 1989; 262: 523–528.
15. Barber JE, Griffin B, Ratliff NB, et al. Mechanical properties of myxomatous mitral valves. J Thorac Cardiovasc Surg. In press.
16. Messier RH, Bass BL, Aly HM, et al. Dual structural and functional phenotypes of the porcine aortic valve interstitial population: characteristics of the leaflet myofibroblast. J Surg Res. 1994; 57: 1–21.[Medline] [Order article via Infotrieve]
17. Mulholland DL, Gotlieb AI. Cell biology of valvular interstitial cells. Can J Cardiol. 1996; 12: 231–236.[Medline] [Order article via Infotrieve]
18. Taylor PM, Allen SP, Yacoub MH. Phenotypic and functional characterization of interstitial cells from human heart valves, pericardium and skin. J Heart Valve Dis. 2000; 9: 150–158.[Medline] [Order article via Infotrieve]
19.
Tjurmin AV, Ananyeva NM, Smith EP, et al. Studies on the histogenesis of myxomatous tissue of human coronary lesions. Arterioscler Thromb Vasc Biol. 1999; 19: 83–97.
20. Bashey RI, Torii S, Angrist A. Age-related collagen and elastin content of heart valves. J Gerontol. 1967; 22: 203–208.[Medline] [Order article via Infotrieve]
21.
Krane SM, Byrne MH, Lemaitre V, et al. Different collagenase gene products have different roles in degradation of type I collagen. J Biol Chem. 1996; 271: 28509–28515.
22. Sukhova GK, Shi G-P, Simon DI, et al. Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. J Clin Invest. 1998; 102: 576–583.[Medline] [Order article via Infotrieve]
23.
Decker RS, Dingle JT. Cardiac catabolic factors: the degradation of heart valve intercellular matrix. Science. 1982; 215: 987–989.
24. Henney AM, Decker RS. Production of a factor by cultured human heart valves that is immunologically related to interleukin-1. Cardiovasc Res. 1986; 21: 21–27.
25.
Galis ZS, Muszynski M, Sukhova G, et al. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ Res. 1994; 75: 181–189.
26. Caulfield JB, Page DL, Kastor JA, et al. Connective tissue abnormalities in spontaneous rupture of chordae tendineae. Arch Pathol. 1971; 91: 537–541.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  E. H. Stephens, T. A. Timek, G. T. Daughters, J. J. Kuo, A. M. Patton, L. S. Baggett, N. B. Ingels, D. C. Miller, and K. J. Grande-Allen Significant Changes in Mitral Valve Leaflet Matrix Composition and Turnover With Tachycardia-Induced Cardiomyopathy Circulation, September 15, 2009; 120(11_suppl_1): S112 - S119. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Combs and K. E. Yutzey VEGF and RANKL Regulation of NFATc1 in Heart Valve Development Circ. Res., September 11, 2009; 105(6): 565 - 574. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Connolly, M. A. Bakay, J. T. Fulmer, R. C. Gorman, J. H. Gorman III, M. A. Oyama, and R. J. Levy Fenfluramine Disrupts the Mitral Valve Interstitial Cell Response to Serotonin Am. J. Pathol., September 1, 2009; 175(3): 988 - 997. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Combs and K. E. Yutzey Heart Valve Development: Regulatory Networks in Development and Disease Circ. Res., August 28, 2009; 105(5): 408 - 421. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Dal-Bianco, E. Aikawa, J. Bischoff, J. L. Guerrero, M. D. Handschumacher, S. Sullivan, B. Johnson, J. S. Titus, Y. Iwamoto, J. Wylie-Sears, et al. Active Adaptation of the Tethered Mitral Valve: Insights Into a Compensatory Mechanism for Functional Mitral Regurgitation Circulation, July 28, 2009; 120(4): 334 - 342. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Gu and K. S. Masters Role of the MAPK/ERK pathway in valvular interstitial cell calcification Am J Physiol Heart Circ Physiol, June 1, 2009; 296(6): H1748 - H1757. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Aikawa, M. Aikawa, P. Libby, J.-L. Figueiredo, G. Rusanescu, Y. Iwamoto, D. Fukuda, R. H. Kohler, G.-P. Shi, F. A. Jaffer, et al. Arterial and Aortic Valve Calcification Abolished by Elastolytic Cathepsin S Deficiency in Chronic Renal Disease Circulation, April 7, 2009; 119(13): 1785 - 1794. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Balachandran, P. Sucosky, H. Jo, and A. P. Yoganathan Elevated cyclic stretch alters matrix remodeling in aortic valve cusps: implications for degenerative aortic valve disease Am J Physiol Heart Circ Physiol, March 1, 2009; 296(3): H756 - H764. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-H. Chen, C. Y. Y. Yip, E. D. Sone, and C. A. Simmons Identification and Characterization of Aortic Valve Mesenchymal Progenitor Cells with Robust Osteogenic Calcification Potential Am. J. Pathol., March 1, 2009; 174(3): 1109 - 1119. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-F. Avierinos, J. Inamo, F. Grigioni, B. Gersh, C. Shub, and M. Enriquez-Sarano Sex Differences in Morphology and Outcomes of Mitral Valve Prolapse Ann Intern Med, December 2, 2008; 149(11): 787 - 794. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Liu and A. I. Gotlieb Transforming Growth Factor-{beta} Regulates in Vitro Heart Valve Repair by Activated Valve Interstitial Cells Am. J. Pathol., November 1, 2008; 173(5): 1275 - 1285. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. J. Schoen Evolving Concepts of Cardiac Valve Dynamics: The Continuum of Development, Functional Structure, Pathobiology, and Tissue Engineering Circulation, October 28, 2008; 118(18): 1864 - 1880. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. W. Benson Thar's Tendons in Them Thar Valves! Circ. Res., October 24, 2008; 103(9): 914 - 915. [Full Text] [PDF]
|
|
|
|
|
|
E. H. Stephens, T. C. Nguyen, A. Itoh, N. B. Ingels Jr, D. C. Miller, and K. J. Grande-Allen The Effects of Mitral Regurgitation Alone Are Sufficient for Leaflet Remodeling Circulation, September 30, 2008; 118(14_suppl_1): S243 - S249. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Chakraborty, J. Cheek, B. Sakthivel, B. J. Aronow, and K. E. Yutzey Shared gene expression profiles in developing heart valves and osteoblast progenitor cells Physiol Genomics, September 17, 2008; 35(1): 75 - 85. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Cushing, P. D. Mariner, J.-T. Liao, E. A. Sims, and K. S. Anseth Fibroblast growth factor represses Smad-mediated myofibroblast activation in aortic valvular interstitial cells FASEB J, June 1, 2008; 22(6): 1769 - 1777. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Han, D. C. Peters, C. J. Salton, D. Bzymek, R. Nezafat, B. Goddu, K. V. Kissinger, P. J. Zimetbaum, W. J. Manning, and S. B. Yeon Cardiovascular magnetic resonance characterization of mitral valve prolapse. J. Am. Coll. Cardiol. Img., May 1, 2008; 1(3): 294 - 303. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Pho, W. Lee, D. R. Watt, C. Laschinger, C. A. Simmons, and C. A. McCulloch Cofilin is a marker of myofibroblast differentiation in cells from porcine aortic cardiac valves Am J Physiol Heart Circ Physiol, April 1, 2008; 294(4): H1767 - H1778. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. W.M. Fedak, P. M. McCarthy, and R. O. Bonow Evolving Concepts and Technologies in Mitral Valve Repair Circulation, February 19, 2008; 117(7): 963 - 974. [Full Text] [PDF]
|
|
|
|
 |
|
 G. De Visscher, H. Blockx, B. Meuris, H. Van Oosterwyck, E. Verbeken, M.-C. Herregods, and W. Flameng Functional and biomechanical evaluation of a completely recellularized stentless pulmonary bioprosthesis in sheep. J. Thorac. Cardiovasc. Surg., February 1, 2008; 135(2): 395 - 404. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. B. Donnelly Cardiac Valvular Pathology: Comparative Pathology and Animal Models of Acquired Cardiac Valvular Diseases Toxicol Pathol, February 1, 2008; 36(2): 204 - 217. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Levine and R. Durst MITRAL VALVE PROLAPSE: A DEEPER LOOK. J. Am. Coll. Cardiol. Img., January 1, 2008; 1(3): 304 - 306. [Full Text] [PDF]
|
|
|
|
 |
|
 R. F. Padera Jr. and F. J. Schoen Pathology of Cardiac Surgery Card. Surg. Adult, January 1, 2008; 3(2008): 111 - 178. [Full Text]
|
|
|
|
 |
|
 X. Meng, L. Ao, Y. Song, A. Babu, X. Yang, M. Wang, M. J. Weyant, C. A. Dinarello, J. C. Cleveland Jr., and D. A. Fullerton Expression of functional Toll-like receptors 2 and 4 in human aortic valve interstitial cells: potential roles in aortic valve inflammation and stenosis Am J Physiol Cell Physiol, January 1, 2008; 294(1): C29 - C35. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Aikawa, M. Nahrendorf, J.-L. Figueiredo, F. K. Swirski, T. Shtatland, R. H. Kohler, F. A. Jaffer, M. Aikawa, and R. Weissleder Osteogenesis Associates With Inflammation in Early-Stage Atherosclerosis Evaluated by Molecular Imaging In Vivo Circulation, December 11, 2007; 116(24): 2841 - 2850. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Liu, V. R. Joag, and A. I. Gotlieb The Emerging Role of Valve Interstitial Cell Phenotypes in Regulating Heart Valve Pathobiology Am. J. Pathol., November 1, 2007; 171(5): 1407 - 1418. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. H Chester and P. M Taylor Molecular and functional characteristics of heart-valve interstitial cells Phil Trans R Soc B, August 29, 2007; 362(1484): 1437 - 1443. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. T Butcher and R. M Nerem Valvular endothelial cells and the mechanoregulation of valvular pathology Phil Trans R Soc B, August 29, 2007; 362(1484): 1445 - 1457. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Aikawa The Balance of Power: The Law of Yin and Yang in Smooth Muscle Cell Fate: Is YY1 a Vascular Protector? Circ. Res., July 20, 2007; 101(2): 111 - 113. [Full Text] [PDF]
|
|
|
|
|
|
E. Aikawa, M. Nahrendorf, D. Sosnovik, V. M. Lok, F. A. Jaffer, M. Aikawa, and R. Weissleder Multimodality Molecular Imaging Identifies Proteolytic and Osteogenic Activities in Early Aortic Valve Disease Circulation, January 23, 2007; 115(3): 377 - 386. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-o Deguchi, M. Aikawa, C.-H. Tung, E. Aikawa, D.-E. Kim, V. Ntziachristos, R. Weissleder, and P. Libby Inflammation in Atherosclerosis: Visualizing Matrix Metalloproteinase Action in Macrophages In Vivo Circulation, July 4, 2006; 114(1): 55 - 62. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. B. Hinton Jr, J. Lincoln, G. H. Deutsch, H. Osinska, P. B. Manning, D. W. Benson, and K. E. Yutzey Extracellular Matrix Remodeling and Organization in Developing and Diseased Aortic Valves Circ. Res., June 9, 2006; 98(11): 1431 - 1438. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. C. Caira, S. R. Stock, T. G. Gleason, E. C. McGee, J. Huang, R. O. Bonow, T. C. Spelsberg, P. M. McCarthy, S. H. Rahimtoola, and N. M. Rajamannan Human Degenerative Valve Disease Is Associated With Up-Regulation of Low-Density Lipoprotein Receptor-Related Protein 5 Receptor-Mediated Bone Formation J. Am. Coll. Cardiol., April 18, 2006; 47(8): 1707 - 1712. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Aikawa, P. Whittaker, M. Farber, K. Mendelson, R. F. Padera, M. Aikawa, and F. J. Schoen Human Semilunar Cardiac Valve Remodeling by Activated Cells From Fetus to Adult: Implications for Postnatal Adaptation, Pathology, and Tissue Engineering Circulation, March 14, 2006; 113(10): 1344 - 1352. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-O Deguchi, E. Aikawa, P. Libby, J. R. Vachon, M. Inada, S. M. Krane, P. Whittaker, and M. Aikawa Matrix Metalloproteinase-13/Collagenase-3 Deletion Promotes Collagen Accumulation and Organization in Mouse Atherosclerotic Plaques Circulation, October 25, 2005; 112(17): 2708 - 2715. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Roberts Another Chromosomal Locus for Mitral Valve Prolapse: Close but No Cigar Circulation, September 27, 2005; 112(13): 1924 - 1926. [Full Text] [PDF]
|
|
|
|
|
|
F. Nesta, M. Leyne, C. Yosefy, C. Simpson, D. Dai, J. E. Marshall, J. Hung, S. A. Slaugenhaupt, and R. A. Levine New Locus for Autosomal Dominant Mitral Valve Prolapse on Chromosome 13: Clinical Insights From Genetic Studies Circulation, September 27, 2005; 112(13): 2022 - 2030. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Fondard, D. Detaint, B. Iung, C. Choqueux, H. Adle-Biassette, M. Jarraya, U. Hvass, J.-P. Couetil, D. Henin, J.-B. Michel, et al. Extracellular matrix remodelling in human aortic valve disease: the role of matrix metalloproteinases and their tissue inhibitors Eur. Heart J., July 1, 2005; 26(13): 1333 - 1341. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Orlandi, A. Ciucci, A. Ferlosio, A. Pellegrino, L. Chiariello, and L. G. Spagnoli Increased Expression and Activity of Matrix Metalloproteinases Characterize Embolic Cardiac Myxomas Am. J. Pathol., June 1, 2005; 166(6): 1619 - 1628. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Rabkin-Aikawa, M. Aikawa, M. Farber, J. R. Kratz, G. Garcia-Cardena, N. T. Kouchoukos, M. B. Mitchell, R. A. Jonas, and F. J. Schoen Clinical pulmonary autograft valves: Pathologic evidence of adaptive remodeling in the aortic site J. Thorac. Cardiovasc. Surg., October 1, 2004; 128(4): 552 - 561. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. A. Walker, K. S. Masters, D. N. Shah, K. S. Anseth, and L. A. Leinwand Valvular Myofibroblast Activation by Transforming Growth Factor-{beta}: Implications for Pathological Extracellular Matrix Remodeling in Heart Valve Disease Circ. Res., August 6, 2004; 95(3): 253 - 260. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Yacoub and L. H. Cohn Novel Approaches to Cardiac Valve Repair: From Structure to Function: Part I Circulation, March 2, 2004; 109(8): 942 - 950. [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Pereira, S. W. van Thiel, J. R. Lindner, F. Roelfsema, E. E. van der Wall, H. Morreau, J. W. A. Smit, J. A. Romijn, and J. J. Bax Increased Prevalence of Regurgitant Valvular Heart Disease in Acromegaly J. Clin. Endocrinol. Metab., January 1, 2004; 89(1): 71 - 75. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Ida, S. A. Boylan, A. L. Weigel, and L. M. Hjelmeland Age-related changes in the transcriptional profile of mouse RPE/choroid Physiol Genomics, November 11, 2003; 15(3): 258 - 262. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. A. Tibayan, F. Rodriguez, F. Langer, M. K. Zasio, L. Bailey, D. Liang, G. T. Daughters, N. B. Ingels Jr, and D. C. Miller Annular remodeling in chronic ischemic mitral regurgitation: ring selection implications Ann. Thorac. Surg., November 1, 2003; 76(5): 1549 - 1555. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.A. Radermecker, R. Limet, C.M. Lapiere, and B. Nusgens Increased mRNA expression of decorin in the prolapsing posterior leaflet of the mitral valve Interactive CardioVascular and Thoracic Surgery, September 1, 2003; 2(3): 389 - 394. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. J. Grande-Allen, B. P. Griffin, N. B. Ratliff, D. M. Cosgrove III, and I. Vesely Glycosaminoglycan profiles of myxomatous mitral leaflets and chordae parallel the severity of mechanical alterations J. Am. Coll. Cardiol., July 16, 2003; 42(2): 271 - 277. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. J. Schoen and R. F. Padera Jr. Cardiac Surgical Pathology Card. Surg. Adult, January 1, 2003; 2(2003): 119 - 185. [Full Text]
|
|
|
|
|
|
W. H. Gaasch and G. P. Aurigemma Inhibition of therenin-angiotensin systemand the left ventricularadaptation to mitral regurgitation J. Am. Coll. Cardiol., April 17, 2002; 39(8): 1380 - 1383. [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||